Stroke, Vol 11, 9-13, Copyright © 1980 by American Heart Association
M Ali, JW McDonald, JJ Thiessen and PE Coates
Compressed and enteric-coated acetylsalicylate (ASA) tablets have been
compared in normal healthy subjects. Plasma ASA and salicylate (SA) were
measured by high pressure liquid chromatography (HPLC). Platelet
cyclooxygenase activity in vitro was studied by a radiometric technique.
Following ingestion of 650 mg of ASA in the form of compressed tablets,
cyclooxygenase activity was inhibited 95% within 45 min. Enzyme activity
was observed to increase within 8 h and reached 10% of control level by 24
h. The pattern suggests that only circulating platelets are affected by ASA
ingestion. Following the administration of 650 mg of ASA as enteric-coated
tablets comparable inhibition of cyclooxygenase activity was observed,
although the effect was delayed, reflecting the delayed appearance of ASA
in the plasma. Return to control levels followed a pattern similar to that
observed with the compressed tablet.
ARTICLES
Plasma acetylsalicylate and salicylate and platelet cyclooxygenase activity following plain and enteric-coated aspirin
This article has been cited by other articles:
![]() |
L. Cullen, L. Kelly, S. O. Connor, and D. J. Fitzgerald Selective Cyclooxygenase-2 Inhibition by Nimesulide in Man J. Pharmacol. Exp. Ther., November 1, 1998; 287(2): 578 - 582. [Abstract] [Full Text] |
||||
![]() |
R. G. Hart and M. J.G. Harrison Aspirin Wars : The Optimal Dose of Aspirin to Prevent Stroke Stroke, April 1, 1996; 27(4): 585 - 587. [Full Text] |
||||
![]() |
G. P. Clagett Antithrombotic Drugs and Vascular Surgery Perspectives in Vascular Surgery and Endovascular Therapy, January 1, 1990; 3(2): 79 - 102. [PDF] |
||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1980 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |